Today: 29 April 2026
Browse Category

TSX:ATCU 15 December 2025 - 25 December 2025

Fortescue Ltd Stock (ASX: FMG) News and Forecasts on 25 December 2025: Copper Expansion, Record Shipments, and the 2026 Iron Ore Outlook

Fortescue Ltd Stock (ASX: FMG) News and Forecasts on 25 December 2025: Copper Expansion, Record Shipments, and the 2026 Iron Ore Outlook

Fortescue shares last traded at A$22.29 on 24 December 2025, up 21% for the year. The company agreed to acquire the remaining 64% of Alta Copper for C$139 million, targeting completion in early 2026. Fortescue reaffirmed FY26 shipment guidance but faces a softer iron ore price outlook for 2026–2027.
25 December 2025
···
Fortescue Ltd Stock (ASX:FMG) Outlook on Dec. 21, 2025: Alta Copper Deal, Iron Ore Forecasts, and What Analysts Expect Next

Fortescue Ltd Stock (ASX:FMG) Outlook on Dec. 21, 2025: Alta Copper Deal, Iron Ore Forecasts, and What Analysts Expect Next

Fortescue Ltd closed at A$21.88 on Dec. 19, down 6.4% from its 52-week high. The company agreed to buy the remaining 64% of Alta Copper for C$1.40 per share, valuing Alta at C$139 million. Alta’s board backed the deal, which targets completion in early 2026. Fortescue aims to expand into copper amid weaker iron ore forecasts and mixed signals from China’s steel sector.
21 December 2025
···
Fortescue Ltd Stock (ASX: FMG) Today: Alta Copper Deal, Analyst Forecasts, and the 2026 Iron Ore & Copper Outlook

Fortescue Ltd Stock (ASX: FMG) Today: Alta Copper Deal, Analyst Forecasts, and the 2026 Iron Ore & Copper Outlook

Fortescue Ltd announced a binding deal to acquire the remaining 64% of Alta Copper Corp for C$1.40 per share in cash, valuing Alta at C$139 million. The purchase gives Fortescue full control of the Cañariaco copper project in Peru. Fortescue shares fell about 0.8% in early trading to around A$22.64. The deal is expected to close in the March quarter of 2026, pending shareholder and court approval.
15 December 2025
···

Stock Market Today

  • Pfizer Share Price Shows Potential Undervaluation Despite Recent Decline
    April 29, 2026, 4:11 AM EDT. Pfizer's (PFE) stock recently dropped 3% over a week and 2.1% over 30 days, closing at $26.48. Despite short-term weakness, the one-year return still stands at 19.4%, outperforming broader declines over 3 and 5 years. A discounted cash flow (DCF) analysis estimates Pfizer's intrinsic value at $64.92 per share, signaling a 59.2% undervaluation compared to its current price. The company's value score is moderate, reflecting mixed signals on undervaluation. Investors consider factors like regulatory pressures, drug pipelines, and sector competition in their evaluations. With a recent free cash flow of $8.5 billion and projected growth to $16.4 billion by 2030, Pfizer's long-term prospects appear solid. The price-to-earnings (P/E) ratio also plays a key role in assessing market expectations against current earnings.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 4:11 AM EDT Pfizer Share Price Shows Potential Undervaluation Despite Recent Decline April 29, 2026, 4:11 AM EDT. Pfizer's (PFE) stock recently dropped 3% over a week and 2.1% over 30 days, closing at $26.48. Despite short-term weakness, the one-year return still stands at 19.4%, outperforming broader declines over 3 and 5 years. A discounted cash flow (DCF) analysis estimates Pfizer's intrinsic value at $64.92 per share, signaling a **59.2% undervaluation** compared to its current price. The company's value score is moderate, reflecting mixed signals on undervaluation. Investors
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Go toTop